{"filing":{"accession_number":"0001213900-26-075757","cik":"0002023016","ticker":"TTRX","company_name":"Turn Therapeutics Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"ea0297061-8k_turn.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/ea0297061-8k_turn.htm"},"events":[{"id":16318,"run_id":14569,"accession_number":"0001213900-26-075757","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Turn Therapeutics announced completion of a comprehensive interim analysis of its Phase 2 clinical trial for GX-03 in atopic dermatitis, resulting in a finalized Stage 2 study design with expanded patient population criteria and optimized endpoints. This represents a material operational and clinical development milestone—the company identified clinically meaningful efficacy across a broader disease severity spectrum than anticipated, enabling prospective expansion of enrollment to include mild-to-moderate disease patients (EASI 1.1-7.0), and adopted the FDA-recognized Hochberg multiple testing procedure for statistical analysis. While this is clinical-stage progress rather than a discrete event type (not earnings, M\u0026A, litigation, etc.), it materially affects investor assessment of the company's development trajectory and regulatory pathway for its lead candidate.","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14384,"accession_number":"0001213900-26-075757","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Turn Therapeutics announced completion of a comprehensive interim analysis of its Phase 2 clinical trial for GX-03 in atopic dermatitis, resulting in a finalized Stage 2 study design with expanded patient population criteria and optimized endpoints. This represents a material operational and clinical development milestone—the company identified clinically meaningful efficacy across a broader disease severity spectrum than anticipated, enabling prospective expansion of enrollment to include mild-to-moderate disease patients (EASI 1.1-7.0), and adopted the FDA-recognized Hochberg multiple testing procedure for statistical analysis. While this is clinical-stage progress rather than a discrete event type (not earnings, M\u0026A, litigation, etc.), it materially affects investor assessment of the company's development trajectory and regulatory pathway for its lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:12:07.951664+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14384,"accession_number":"0001213900-26-075757","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Turn Therapeutics announced completion of a comprehensive interim analysis of its Phase 2 clinical trial for GX-03 in atopic dermatitis, resulting in a finalized Stage 2 study design with expanded patient population criteria and optimized endpoints. This represents a material operational and clinical development milestone—the company identified clinically meaningful efficacy across a broader disease severity spectrum than anticipated, enabling prospective expansion of enrollment to include mild-to-moderate disease patients (EASI 1.1-7.0), and adopted the FDA-recognized Hochberg multiple testing procedure for statistical analysis. While this is clinical-stage progress rather than a discrete event type (not earnings, M\u0026A, litigation, etc.), it materially affects investor assessment of the company's development trajectory and regulatory pathway for its lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:12:07.951664+00:00","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-07-07"}]}